Preclinical evaluation of the ROR1-targeting antibody-drug conjugates zilovertamab vedotin and VLS-211 against B-cell ALL patient-derived xenografts.
Saved in:
| Title: | Preclinical evaluation of the ROR1-targeting antibody-drug conjugates zilovertamab vedotin and VLS-211 against B-cell ALL patient-derived xenografts. |
|---|---|
| Authors: | Smith CM; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health UNSW Centre for Childhood Cancer Research, UNSW Sydney Sydney New South Wales Australia., Watts B; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health UNSW Centre for Childhood Cancer Research, UNSW Sydney Sydney New South Wales Australia., Evans K; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health UNSW Centre for Childhood Cancer Research, UNSW Sydney Sydney New South Wales Australia., Kosasih H; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health UNSW Centre for Childhood Cancer Research, UNSW Sydney Sydney New South Wales Australia., Mayoh C; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health UNSW Centre for Childhood Cancer Research, UNSW Sydney Sydney New South Wales Australia., Erickson SW; RTI International, Research Triangle Park North Carolina USA., Earley EJ; RTI International, Research Triangle Park North Carolina USA., Neuhauser S; The Jackson Laboratory for Mammalian Genetics Bar Harbor Maine USA., Stearns TM; The Jackson Laboratory for Mammalian Genetics Bar Harbor Maine USA., Philip VM; The Jackson Laboratory for Mammalian Genetics Bar Harbor Maine USA., Chuang JH; The Jackson Laboratory for Genomic Medicine Farmington Connecticut USA., de Bock CE; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health UNSW Centre for Childhood Cancer Research, UNSW Sydney Sydney New South Wales Australia., Bowman EP; Department of Oncology Merck & Co. Inc. Rahway New Jersey USA., Jessen KA; Formerly VelosBio Inc. San Diego California USA., Jocoy EL; The Jackson Laboratory Sacramento California USA., Bult CJ; The Jackson Laboratory for Mammalian Genetics Bar Harbor Maine USA., Teicher BA; National Cancer Institute Bethesda Maryland USA., Smith MA; National Cancer Institute Bethesda Maryland USA., Lock RB; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health UNSW Centre for Childhood Cancer Research, UNSW Sydney Sydney New South Wales Australia. |
| Source: | HemaSphere [Hemasphere] 2026 Jul 22; Vol. 10 (7), pp. e70438. Date of Electronic Publication: 2026 Jul 22 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
